Ethynodiol Diacetate And Ethinyl Estradiol Tablets

Generic Name: ethynodiol diacetate and ethinyl estradiol tablets

Over-the-Counter (OTC)

Brand Names:

Zovia 1/35

DESCRIPTION Zovia 1/35: Each pale pink tablet contains 1 mg of ethynodiol diacetate and 35 mcg of ethinyl estradiol, and the inactive ingredients include lactose monohydrate, pregelatinized starch, vitamin e, magnesium stearate, microcrystalline cellulose, croscarmellose sodium, povidone, polyvinyl alcohol, titanium dioxide, talc, polyethylene glycol/macrogol, lecithin (soya), FD&C Red #40 aluminum lake, FD&C Blue #1 aluminum lake, and FD&C yellow #6 aluminum lake.

Overview

DESCRIPTION Zovia 1/35: Each pale pink tablet contains 1 mg of ethynodiol diacetate and 35 mcg of ethinyl estradiol, and the inactive ingredients include lactose monohydrate, pregelatinized starch, vitamin e, magnesium stearate, microcrystalline cellulose, croscarmellose sodium, povidone, polyvinyl alcohol, titanium dioxide, talc, polyethylene glycol/macrogol, lecithin (soya), FD&C Red #40 aluminum lake, FD&C Blue #1 aluminum lake, and FD&C yellow #6 aluminum lake.

Uses

INDICATIONS AND USAGE Zovia 1/35 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization and progestogen implants and injections, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. (A) Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.

Dosage

DOSAGE AND ADMINISTRATION To achieve maximum contraceptive effectiveness, oral contraceptives must be taken exactly as directed and at intervals of 24 hours. IMPORTANT: If the Sunday start schedule is selected, the patient should be instructed to use an additional method of protection until after the first week of administration in the initial cycle. The possibility of ovulation and conception prior to initiation of use should be considered. Zovia 1/35 Dosage Schedules The Zovia 1/35 tablet dispensers contain 21 pale pink active tablets arranged in three numbered rows of 7 tablets each, followed by a fourth row of 7 white placebo (inactive) tablets . Days of the week are embossed on the plastic compact just above the tablets, starting with Sunday on the left.

Side Effects

ADVERSE REACTIONS An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see WARNINGS ): ● Thrombophlebitis and thrombosis ● Arterial thromboembolism ● Pulmonary embolism ● Myocardial infarction and coronary thrombosis ● Cerebral hemorrhage ● Cerebral thrombosis ● Hypertension ● Gallbladder disease ● Benign and malignant liver tumors, and other hepatic lesions There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed: ● Mesenteric thrombosis ● Neuro-ocular lesions (e.g., retinal thrombosis and optic neuritis) The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-re...

Warnings

WARNING SIGNALS If any of these adverse effects occur while you are taking oral contraceptives, call your doctor immediately: ● Sharp chest pain, coughing up blood, or sudden shortness of breath (indicating a possible blood clot in the lung). ● Pain in the calf (indicating a possible blood clot in the leg). ● Crushing chest pain or heaviness in the chest (indicating a possible heart attack). ● Sudden severe headache or vomiting, dizziness or fainting, disturbances of vision or speech, or numbness in an arm or leg (indicating a possible stroke). ● Sudden partial or complete loss of vision (indicating a possible blood clot in the blood vessels of the eye). ● Breast lumps (indicating possible breast cancer or fibrocystic disease of the breast). CONTRAINDICATIONS Oral contraceptives should not be used in women who have the following conditions: ● Thrombophlebitis or thromboembolic disorders ● A past history of deep vein thrombophlebitis or thromboembolic disorders ● Cerebral vascular disease, myocardial infarction, or coronary artery disease, or a past history of these conditions ● Known or suspected carcinoma of the breast, or a history...

Storage

HOW SUPPLIED Zovia 1/35: Each pale pink Zovia 1/35 tablet is round, biconvex, unscored, debossed with X1 on one side and contains 1 mg of ethynodiol diacetate and 35 mcg of ethinyl estradiol. Zovia 1/35 is packaged in cartons of three (NDC 51862-894-03) and six (NDC 51862-894-06) tablet compact dispensers. Each compact dispenser contains 21 pale pink tablets and 7 white placebo tablets.

Frequently Asked Questions

What is Ethynodiol Diacetate And Ethinyl Estradiol Tablets used for?

INDICATIONS AND USAGE Zovia 1/35 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization and progestogen implants and injections, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. (A) Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.

What are the side effects of Ethynodiol Diacetate And Ethinyl Estradiol Tablets?

ADVERSE REACTIONS An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see WARNINGS ): ● Thrombophlebitis and thrombosis ● Arterial thromboembolism ● Pulmonary embolism ● Myocardial infarction and coronary thrombosis ● Cerebral hemorrhage ● Cerebral thrombosis ● Hypertension ● Gallbladder disease ● Benign and malignant liver tumors, and other hepatic lesions There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed: ● Mesenteric thrombosis ● Neuro-ocular lesions (e.g., retinal thrombosis and optic neuritis) The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-re...

What are the important warnings for Ethynodiol Diacetate And Ethinyl Estradiol Tablets?

WARNING SIGNALS If any of these adverse effects occur while you are taking oral contraceptives, call your doctor immediately: ● Sharp chest pain, coughing up blood, or sudden shortness of breath (indicating a possible blood clot in the lung). ● Pain in the calf (indicating a possible blood clot in the leg). ● Crushing chest pain or heaviness in the chest (indicating a possible heart attack). ● Sudden severe headache or vomiting, dizziness or fainting, disturbances of vision or speech, or numbness in an arm or leg (indicating a possible stroke). ● Sudden partial or complete loss of vision (indicating a possible blood clot in the blood vessels of the eye). ● Breast lumps (indicating possible breast cancer or fibrocystic disease of the breast). CONTRAINDICATIONS Oral contraceptives should not be used in women who have the following conditions: ● Thrombophlebitis or thromboembolic disorders ● A past history of deep vein thrombophlebitis or thromboembolic disorders ● Cerebral vascular disease, myocardial infarction, or coronary artery disease, or a past history of these conditions ● Known or suspected carcinoma of the breast, or a history...

Related Medications

Medical Disclaimer

This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.